MIT researchers have developed a new ingestible capsule that can release insulin directly into the stomach and could be used to treat type 2 diabetes, reports Joe Palca for NPR. "We chose the stomach as the site of delivery because we recognized that the stomach is a thick and robust part of the GI tract," explains visiting scientist Giovanni Traverso.
Wired reporter Megan Molteni writes that MIT researchers have developed an ingestible capsule that could be used to deliver insulin to diabetes patients. The researchers were inspired by the leopard tortoise to create a self-orienting device that can position itself to deliver medication directly into the stomach. “The result was a roly-poly-pill that autonomously rights itself to be needle-down,” Molteni explains.
Associated Press reporter Lauran Neergaard writes that MIT researchers have created a pea-sized pill that, once swallowed, can deliver medications such as insulin directly to the stomach. “The way this works is it travels down the esophagus in seconds, it’s in the stomach within a few minutes, and then you get the drug,” explains visiting scientist Giovanni Traverso.
Inspired by the shell of a leopard tortoise, MIT researchers have developed a self-orienting ingestible capsule that can deliver doses of medication to the stomach, writes Megan Thielking for STAT. “If we’re able to deliver large molecules orally, it would not only change drug delivery but also drug discovery,” says Prof. Robert Langer.
A team of MIT researchers has created a tiny ingestible device that deliver medications such as insulin directly to the stomach and could replace the daily injections used to treat diabetes patients, reports Alice Park for TIME. “We see no reason why someday this couldn’t be used to deliver any protein to the body,” says Prof. Robert Langer.
Boston Globe reporter Martin Finucane writes that MIT researchers have developed an ingestible capsule that contains a small needle that injects insulin directly into the stomach. Finucane writes that the researchers “designed the pill with a special shape to ensure that it will fall and then orient itself at the bottom of the stomach so that the needle is facing toward the stomach lining rather than the stomach’s inside.”
Forbes contributor Angelica Krystle Donati highlights a recent presentation by Prof. Robert Langer, in which he shared his experience founding more than 40 startups.
MIT researchers have developed an inhalable form of messenger RNA that could be used to help treat patients with lung disease, reports Christopher Intagliata for Scientific American. Intagliata explains that researchers hope to one day “use this technique to help cystic fibrosis patients.”
MIT researchers have developed a remote-controlled ingestible capsule that can be operated by a user’s smartphone, reports the Xinhua news agency. “The researchers envisioned that this type of sensor could be used to diagnose early signs of disease and then respond with the appropriate medication,” Xinhua explains.
HealthDay News reporter E.J. Mundell writes that MIT researchers have developed an ingestible capsule that can be used to monitor health a patient’s health. “The capsule could deliver drugs as well as sense the condition of its surroundings in the gut, including infections or allergic reactions,” Mundell explains.
MIT researchers have developed a new injectable material that can deliver medication through cartilage and could one day be used to help reverse osteoarthritis, reports Katie Camero for The Boston Globe. Camero explains that the new material “can penetrate deep into the tissue, delivering drugs that can potentially help the chondrocytes heal cartilage.”
STAT reporter Kate Sheridan writes about MIT startup SQZ Biotech, which is developing a “technology that will squeeze cells to open up tiny pores in their membranes to deliver gene therapies or medicines straight into the cell.”
MIT startup Lyndra has found that an ingestible device originally developed by researchers from MIT and Brigham and Women’s Hospital can help tackle the problem of medication adherence, reports Kate Sheridan for STAT. The new technology could make it possible for patients to take “one pill a week for conditions as varied as Alzheimer’s, addiction, allergies, malaria, schizophrenia, high cholesterol, and HIV.”
Writing for the American History Magazine, Sarah Richardson highlights the trailblazing path of Ellen Swallow Richards. Richardson notes that Swallow Richards was a “one-woman parade of firsts: first female student at Massachusetts Institute of Technology, first female fellow of the American Association of Mining and Metallurgy, first female professor at MIT.”
Researchers from MIT are using the brittle nature of graphene to mass produce cell-sized robots, writes David Grossman of Popular Mechanics. Called “syncells” or synthetic cells, the researchers hope they can be used in biomedical testing. “Inject hundreds into the bloodstreams and let the data fly back into sensors,” explains Grossman.